BibTex format

author = {George, PM and Reed, A and Desai, SR and Devaraj, A and Faiez, TS and Laverty, S and Kanwal, A and Esneau, C and Liu, MKC and Kamal, F and Man, WD-C and Kaul, S and Singh, S and Lamb, G and Faizi, FK and Schuliga, M and Read, J and Burgoyne, T and Pinto, AL and Micallef, J and Bauwens, E and Candiracci, J and Bougoussa, M and Herzog, M and Raman, L and Ahmetaj-Shala, B and Turville, S and Aggarwal, A and Farne, HA and Dalla, Pria A and Aswani, AD and Patella, F and Borek, WE and Mitchell, JA and Bartlett, NW and Dokal, A and Xu, X-N and Kelleher, P and Shah, A and Singanayagam, A},
doi = {10.1126/scitranslmed.abo5795},
journal = {Science Translational Medicine},
pages = {1--16},
title = {A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae.},
url = {},
volume = {14},
year = {2022}

RIS format (EndNote, RefMan)

AB - Interstitial lung disease and associated fibrosis occur in a proportion of individuals who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through unknown mechanisms. We studied individuals with severe coronavirus disease 2019 (COVID-19) after recovery from acute illness. Individuals with evidence of interstitial lung changes at 3 to 6 months after recovery had an up-regulated neutrophil-associated immune signature including increased chemokines, proteases, and markers of neutrophil extracellular traps that were detectable in the blood. Similar pathways were enriched in the upper airway with a concomitant increase in antiviral type I interferon signaling. Interaction analysis of the peripheral phosphoproteome identified enriched kinases critical for neutrophil inflammatory pathways. Evaluation of these individuals at 12 months after recovery indicated that a subset of the individuals had not yet achieved full normalization of radiological and functional changes. These data provide insight into mechanisms driving development of pulmonary sequelae during and after COVID-19 and provide a rational basis for development of targeted approaches to prevent long-term complications.
AU - George,PM
AU - Reed,A
AU - Desai,SR
AU - Devaraj,A
AU - Faiez,TS
AU - Laverty,S
AU - Kanwal,A
AU - Esneau,C
AU - Liu,MKC
AU - Kamal,F
AU - Man,WD-C
AU - Kaul,S
AU - Singh,S
AU - Lamb,G
AU - Faizi,FK
AU - Schuliga,M
AU - Read,J
AU - Burgoyne,T
AU - Pinto,AL
AU - Micallef,J
AU - Bauwens,E
AU - Candiracci,J
AU - Bougoussa,M
AU - Herzog,M
AU - Raman,L
AU - Ahmetaj-Shala,B
AU - Turville,S
AU - Aggarwal,A
AU - Farne,HA
AU - Dalla,Pria A
AU - Aswani,AD
AU - Patella,F
AU - Borek,WE
AU - Mitchell,JA
AU - Bartlett,NW
AU - Dokal,A
AU - Xu,X-N
AU - Kelleher,P
AU - Shah,A
AU - Singanayagam,A
DO - 10.1126/scitranslmed.abo5795
EP - 16
PY - 2022///
SN - 1946-6234
SP - 1
TI - A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae.
T2 - Science Translational Medicine
UR -
UR -
UR -
UR -
VL - 14
ER -